RU2018122012A - БИС-пиридазиновые соединения и их применение в лечении рака - Google Patents

БИС-пиридазиновые соединения и их применение в лечении рака Download PDF

Info

Publication number
RU2018122012A
RU2018122012A RU2018122012A RU2018122012A RU2018122012A RU 2018122012 A RU2018122012 A RU 2018122012A RU 2018122012 A RU2018122012 A RU 2018122012A RU 2018122012 A RU2018122012 A RU 2018122012A RU 2018122012 A RU2018122012 A RU 2018122012A
Authority
RU
Russia
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
methoxy
Prior art date
Application number
RU2018122012A
Other languages
English (en)
Russian (ru)
Inventor
Морис Реймонд Верскойл Финлей
Original Assignee
Астразенека Аб
Кэнсер Рисерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб, Кэнсер Рисерч Текнолоджи Лимитед filed Critical Астразенека Аб
Publication of RU2018122012A publication Critical patent/RU2018122012A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2018122012A 2015-11-27 2016-11-25 БИС-пиридазиновые соединения и их применение в лечении рака RU2018122012A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1520959.6A GB201520959D0 (en) 2015-11-27 2015-11-27 Bis-pyridazine compounds and their use in treating cancer
GB1520959.6 2015-11-27
PCT/EP2016/078899 WO2017089587A1 (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
RU2018122012A true RU2018122012A (ru) 2019-12-30

Family

ID=55177338

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018122012A RU2018122012A (ru) 2015-11-27 2016-11-25 БИС-пиридазиновые соединения и их применение в лечении рака

Country Status (17)

Country Link
US (2) US10196382B2 (enExample)
EP (1) EP3380468B8 (enExample)
JP (1) JP2018535226A (enExample)
KR (1) KR20180083426A (enExample)
CN (1) CN108349951B (enExample)
AR (1) AR106849A1 (enExample)
AU (1) AU2016360970B2 (enExample)
CA (1) CA3005102A1 (enExample)
DK (1) DK3380468T3 (enExample)
ES (1) ES2806723T3 (enExample)
GB (1) GB201520959D0 (enExample)
IL (1) IL259358A (enExample)
MX (1) MX2018006374A (enExample)
RU (1) RU2018122012A (enExample)
SG (1) SG11201803814SA (enExample)
TW (1) TW201731837A (enExample)
WO (1) WO2017089587A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106552296B (zh) 2015-09-29 2020-08-14 上海氪励铵勤科技发展有限公司 纳米粒子、其制备方法与结石取出装置及应用
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
KR20250137464A (ko) 2024-03-11 2025-09-18 이석재 숏블라스트머신의 연마재탱크

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785305B (zh) 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160100407A (ko) * 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
CN108349951B (zh) 2020-11-13
CN108349951A (zh) 2018-07-31
AR106849A1 (es) 2018-02-21
US10577354B2 (en) 2020-03-03
AU2016360970B2 (en) 2019-11-07
GB201520959D0 (en) 2016-01-13
IL259358A (en) 2018-07-31
US20190169172A1 (en) 2019-06-06
US10196382B2 (en) 2019-02-05
TW201731837A (zh) 2017-09-16
US20170152244A1 (en) 2017-06-01
WO2017089587A1 (en) 2017-06-01
MX2018006374A (es) 2019-07-08
KR20180083426A (ko) 2018-07-20
CA3005102A1 (en) 2017-06-01
EP3380468B8 (en) 2020-11-04
EP3380468B1 (en) 2020-05-20
EP3380468A1 (en) 2018-10-03
JP2018535226A (ja) 2018-11-29
AU2016360970A1 (en) 2018-07-05
ES2806723T3 (es) 2021-02-18
SG11201803814SA (en) 2018-06-28
DK3380468T3 (da) 2020-07-27

Similar Documents

Publication Publication Date Title
RU2460730C2 (ru) Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
PH12019501707A1 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
RU2018123714A (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
RU2017105353A (ru) Соединения
JP2019517487A5 (enExample)
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
RU2017116197A (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера
IL264982B (en) Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
JP2016515561A5 (enExample)
EA201690959A1 (ru) Способ синтеза ингибитора индоламин-2,3-диоксигеназы
JP2016040288A5 (enExample)
JP2017505293A5 (enExample)
JP2016522254A5 (enExample)
JP2017517512A5 (enExample)
RU2017145649A (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ НА ОСНОВЕ АНТИТЕЛА К CD20 В СОЧЕТАНИИ С ИНГИБИТОРОМ BeI-2 И ИНГИБИТОРОМ MDM2
RU2015135824A (ru) Бициклические соединения пиримидона в качестве ингибиторов lp-pla2
JP2018535986A5 (enExample)
RU2017117566A (ru) Активатор kcnq2-5 каналов
JP2015521195A5 (enExample)
JP2018535235A5 (enExample)
RU2016132858A (ru) Производные фторнафтила

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20191126